You just read:

Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

News provided by

Mallinckrodt plc

Nov 11, 2019, 15:30 ET